AEON Biopharma Inc Ordinary Shares - Class A AEON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
AEON Biopharma Holds Meeting With FDA for Botox Biosimilar
Trading Information
- Previous Close Price
- $0.13
- Day Range
- $0.12–0.13
- 52-Week Range
- $0.11–1.45
- Bid/Ask
- $0.12 / $0.13
- Shares Outstanding
- 84.12M
- Market Cap
- $10.35M
- Volume/Avg
- 1M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 8
Valuation
Metric | AEON |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AEON
Financial Strength
Metric | AEON |
|---|---|
Quick Ratio | 2.50 |
Current Ratio | 2.75 |
Interest Coverage | — |
Quick Ratio
AEON
Profitability
Metric | AEON |
|---|---|
Return on Assets (Normalized) | −173.30% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AEON
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$c!T?c | LOCK|f&h!Z | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|$<@rx<G | LOCK|>qL% | $96B | |||
| Moderna Inc MRNA | LOCK|RyCDr< | LOCK|HF | $81B | |||
| argenx SE ADR ARGX | LOCK|&j%#@&^ | LOCK|Jd | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|rfJ^qn | LOCK|f$^ | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|McJ#!<k | LOCK|#Wp& | $30B | |||
| Incyte Corp INCY | LOCK|$$vB$Cj | LOCK|@p$ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|&c&^^DF | LOCK|G<r | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|cb@&!f | LOCK|rG@%R | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|l?p^JL | LOCK|@@ | $15B |